

Dominick BossÃ©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8613761/publications.pdf>

Version: 2024-02-01

59
papers

2,474
citations

471061

17
h-index

233125

45
g-index

62
all docs

62
docs citations

62
times ranked

5198
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. <i>Science</i> , 2018, 359, 801-806.	6.0	898
2	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. <i>Cancer Immunology Research</i> , 2017, 5, 312-318.	1.6	354
3	Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. , 2018, 6, 5.		200
4	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. <i>Nature Communications</i> , 2019, 10, 4346.	5.8	139
5	Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 581-590.	5.1	124
6	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-“Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018, 6, 758-765.	1.6	89
7	Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3615-3623.	0.8	65
8	Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2020, 3, 372-381.	2.6	59
9	Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. <i>Cancer Immunology Research</i> , 2018, 6, 402-408.	1.6	56
10	Pan-urolologic cancer genomic subtypes that transcend tissue of origin. <i>Nature Communications</i> , 2017, 8, 199.	5.8	49
11	Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis. <i>Cancer</i> , 2018, 124, 925-933.	2.0	38
12	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. , 2017, 5, 66.		37
13	Radiogenomics in renal cell carcinoma. <i>Abdominal Radiology</i> , 2019, 44, 1990-1998.	1.0	37
14	Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 118, 1238-1242.	2.9	33
15	Total liquid ventilation efficacy in an ovine model of severe meconium aspiration syndrome. <i>Critical Care Medicine</i> , 2011, 39, 1097-1103.	0.4	30
16	PROSPECT Eligibility and Clinical Outcomes: Results From the Pan-Canadian Rectal Cancer Consortium. <i>Clinical Colorectal Cancer</i> , 2016, 15, 243-249.	1.0	29
17	Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 707-712.	2.9	28
18	Measurement of Fractional Order Model Parameters of Respiratory Mechanical Impedance in Total Liquid Ventilation. <i>IEEE Transactions on Biomedical Engineering</i> , 2012, 59, 323-331.	2.5	24

#	ARTICLE	IF	CITATIONS
19	Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. <i>Clinical Cancer Research</i> , 2018, 24, 4081-4088.	3.2	24
20	Immunotherapy in the Elderly. <i>European Urology Focus</i> , 2017, 3, 403-412.	1.6	16
21	Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic. <i>Canadian Urological Association Journal</i> , 2019, 14, E154-E158.	0.3	15
22	Imaging Intensity and Survival Outcomes in High-Risk Resected Melanoma Treated by Systemic Therapy at Recurrence. <i>Annals of Surgical Oncology</i> , 2020, 27, 3683-3691.	0.7	13
23	Antibiotic use and outcomes with systemic therapy in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 607-607.	0.8	12
24	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. <i>Canadian Urological Association Journal</i> , 2020, 15, 84-97.	0.3	11
25	A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 148, 102896.	2.0	10
26	Clinician-Scientist Trainee: A German Perspective. <i>Clinical and Investigative Medicine</i> , 2011, 34, 324.	0.3	10
27	Response of Primary Renal Cell Carcinoma to Systemic Therapy. <i>European Urology</i> , 2019, 76, 852-860.	0.9	9
28	Evolution in upfront treatment strategies for metastatic RCC. <i>Nature Reviews Urology</i> , 2020, 17, 73-74.	1.9	9
29	Neonatal total liquid ventilation: is low-frequency forced oscillation technique suitable for respiratory mechanics assessment?. <i>Journal of Applied Physiology</i> , 2010, 109, 501-510.	1.2	6
30	The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicity. <i>Medical Oncology</i> , 2019, 36, 18.	1.2	6
31	Experimental Validation of Cardiac Index Measurement Using Transpulmonary Thermodilution Technique in Neonatal Total Liquid Ventilation. <i>ASAIO Journal</i> , 2010, 56, 557-562.	0.9	4
32	Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts. <i>JCO Global Oncology</i> , 2020, 6, 293-306.	0.8	4
33	Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 863-868.	1.1	4
34	Cabozantinib (Cabo) in advanced non-clear cell renal cell carcinoma (nccRCC): A retrospective multicenter analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4579-4579.	0.8	4
35	Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1089-e1094.	0.9	3
36	Potential insights from population kinetic assessment of progression-free survival curves. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103039.	2.0	3

#	ARTICLE	IF	CITATIONS
37	Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. Journal of Clinical Oncology, 2019, 37, 568-568.	0.8	3
38	Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews. Drugs, 2022, , .	4.9	3
39	Utility of FDG-PET/CT in Patients with Advanced Renal Cell Carcinoma with Osseous Metastases: Comparison with CT and 99mTc-MDP Bone Scan in a Prospective Clinical Trial. Kidney Cancer, 2019, 3, 241-251.	0.2	2
40	Abstract 1774: Progression-free survival curves suggest a dichotomous determinant of PD-L1 inhibitor efficacy. , 2017, , .		2
41	Attitudes towards openâ€label versus placeboâ€control designs in oncology randomized trials: A survey of medical oncologists. Journal of Evaluation in Clinical Practice, 2022, , .	0.9	2
42	Evaluation of disease-free survival as an intermediate metric for overall survival in localized renal cell carcinoma: A trial-level meta-analysis.. Journal of Clinical Oncology, 2017, 35, 4585-4585.	0.8	1
43	Factors impacting progression-free survival (PFS) as a predictor of overall survival (OS).. Journal of Clinical Oncology, 2018, 36, 6556-6556.	0.8	1
44	Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, 626-626.	0.8	1
45	Population kinetics of progression free survival (PFS).. Journal of Clinical Oncology, 2019, 37, e18251-e18251.	0.8	1
46	Surviv du programme scientifique du congrÃ©s annuel de la SCRC-ACCFC 2009. Clinical and Investigative Medicine, 2010, 33, 73.	0.3	1
47	Comparison of tumor mutational burden (TMB) in PBRM1/BAP1-based subsets of advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2018, 36, 634-634.	0.8	1
48	P3.02c-073 Evidence Suggesting a Dichotomous â€Present vs absentâ€Determinant of PDL1 Inhibitor Efficacy in Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2017, 12, S1321.	0.5	0
49	Scientific overview: CSCI-CITAC annual general meeting and young investigatorâ€™s forum 2010. Clinical and Investigative Medicine, 2011, 34, 105.	0.3	0
50	PROSPECT eligibility and clinical outcomes: Results from the pan-Canadian rectal cancer consortium.. Journal of Clinical Oncology, 2015, 33, 6594-6594.	0.8	0
51	Does absolute gain in progression-free survival (PFS) half-life ($t_{1/2}$) translate into absolute overall survival (OS) benefit?. Journal of Clinical Oncology, 2016, 34, e18135-e18135.	0.8	0
52	Evaluating the impact of bone-targeted agents in the era of novel androgen targeted therapy for metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2017, 35, e16500-e16500.	0.8	0
53	Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.. Journal of Clinical Oncology, 2018, 36, 667-667.	0.8	0
54	Renal cell carcinoma (RCC) primary tumor shrinkage on vascular endothelial growth factor (VEGF)-targeted therapy (TT): A pooled analysis.. Journal of Clinical Oncology, 2018, 36, 629-629.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Abstract 1644: Progression-free survival (PFS) as a surrogate for overall survival (OS)., 2018, , .		0
56	Genomic and clinical determinants of recurrence in localized clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology, 2019, 37, 664-664.	0.8	0
57	Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer.. Journal of Clinical Oncology, 2019, 37, e16501-e16501.	0.8	0
58	The role of an open-label non-intervention design versus a placebo-control arm in oncology randomized trials.. Journal of Clinical Oncology, 2020, 38, e14099-e14099.	0.8	0
59	Outcomes of second-line therapies in patients with metastatic de novo small cell prostate cancer (SCPC) and treatment-emergent neuroendocrine prostate cancer (tNEPC).. Journal of Clinical Oncology, 2022, 40, e17022-e17022.	0.8	0